Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Bruce Wysocki who wrote (1265)	7/3/1999 12:41:00 PM
From: Chuca Marsh	Read Replies (1) \| Respond to of 1501

biz.yahoo.com TB type B Test KIT, Just released on this Weeks Edgar on this penny Company, was IZP's TB Test Kit for A and B as I remember all the others also? Foggy, need info. TEXT: .. Nevertheless, the Company continues to receive requests for generic pharmaceutical products from both the public and private sectors in West Africa, and as noted above, ETLC has arranged for the delivery samples, certificates of analysis and related documents for over thirty pharmaceutical products. The Company has sourced these products from pharmaceutical manufacturers in India at pricing levels that will permit the Company to achieve satisfactory gross profit margins. The Company hopes to begin to deliver these products and receive products requests and purchase orders before the end of the third quarter of 1999. In order to enhance its ability to increase the size of its purchase orders and indeed its ability to source generic pharmaceutical products, the Company has recently entered into agreements with an additional manufacturer of generic pharmaceuticals in India. The Company is also seeking to secure rights from a manufacturer of a Hepatitis B diagnostic test kit from India for marketing in Africa, South America, Europe and Asia, for the purpose of generating additional sales revenues and customers for the Company. There can be no assurance that the Company will be successful in securing rights to market the Hepatitis B test kit, or if successful in securing such rights that it will be able to generate sales of such product in any market. The Company during 1998 continued efforts to both increase its product lines and the effectiveness of its West African representation, for the purpose of hopefully establishing a base for increased sales revenues before the end of 1999. The Company has also recently been informed by its representative in Brazil that following the final stage of human testing and the registration of the US manufactured dengue fever test kit that it has received approval for the sale of the test kit in the State of Roraima. In fact, during May, 1999, the first shipment under the order for 2000 dengue fever test kits were made and the Company projects increased orders from other States in Brazil with the approval of the National Health Foundation, Brazil's equivalent of the FDA. The sale of the dengue fever test kits, which required longer approval time than the Company initially anticipated in 1998, commenced with the start of the Brazilian rainy season. With final approvals from Brazil, the Company could generate increased sales of dengue fever test kits for the entire country annually, although there can be no assurance as to the timing or amount of actual sales. However, the Company has been informed that dengue fever is becoming an increasingly more serious disease in Brazil (and elsewhere in the world's tropical climates) and the Company believes that it should be able to generate orders for dengue fever test kits from West Africa as well as Brazil during 1999 and thereafter. The ability to generate increasing orders in the future shall be dependent, in part, on the Company's concluding an extension of its arrangement with ETLC, among other parties. Generic pharmaceuticals are an extremely cost sensitive market, especially in developing countries where the Company is doing business. This has led the Company and its consultants together with their new representatives to devote a significant period of time during 1998 to the establishment and furthering of relationships in West Africa and Brazil, as well as sourcing generic pharmaceuticals and diagnostic test kits at competitive pricing. ... Chucka- <<..The Company is also seeking to secure rights from a manufacturer of a Hepatitis B diagnostic test kit from India for marketing in Africa, South America, Europe and Asia,..>> quote.yahoo.com ADGI - E was droped since 1 July 99 ??? ? I have no info. What is the thoughts...I bot IZP for the TB Testkit mainly...maybe a block here is worth it? These guys at FG are sending out mailings today on LNNE: fools-gold.com